Skip to Main Content

Author Details

Fang-Shu Ou
Mayo Clinic
2007
94
33
PMIDPaper TitleJournal TitlePublished Year
37992266DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.J Clin Oncol2024
36067452Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).J Clin Oncol2023
37627145Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.Cancers (Basel)2023
37549913Changes in Prescribing Patterns in Stage III Colon Cancer.J Natl Compr Canc Netw2023
35904874Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405.Int J Cancer2023
34636852Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.J Natl Cancer Inst2022
35412430Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).Epigenetics2022
35380713Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.Oncologist2022
35641198Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance).Oncologist2022
36117191ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.Nat Commun2022
35191970Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.JAMA Netw Open2022
35179586Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA Netw Open2022
35176136Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.Clin Cancer Res2022
34995084Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).J Clin Oncol2022
35105521Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.J Geriatr Oncol2022
35324465Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).Endocr Relat Cancer2022
34728807Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.Oncogene2022
32958699Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).Clin Cancer Res2021
33604969Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.Oncologist2021
34439209Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.Cancers (Basel)2021
34374082Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931).Cancer2021
34778691FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.JCO Precis Oncol2021
34104867Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).JNCI Cancer Spectr2021
34077237Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.J Clin Oncol2021
33439695Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.J Clin Oncol2021
32499312The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance).Cancer Epidemiol Biomarkers Prev2020
31826977Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.Oncologist2020
33426464IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.JNCI Cancer Spectr2020
33134818Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405.JNCI Cancer Spectr2020
33125497Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial.JAMA Netw Open2020
32940631Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.JAMA Oncol2020
32632268ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.Nat Rev Clin Oncol2020
30623420Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).Int J Cancer2019
31872158Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials.Contemp Clin Trials Commun2019
32259016Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance).JNCI Cancer Spectr2019
32190807Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies.JCO Precis Oncol2019
31268798Reply to S. Sorscher.J Clin Oncol2019
31408415Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.J Clin Oncol2019
31548349Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).Clin Cancer Res2019
31418130Perioperative Gemcitabineâ¿¿+â¿¿Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.Ann Surg Oncol2019
30865548Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.J Clin Oncol2019
31042420Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).J Clin Oncol2019
30806485Milestone prediction for time-to-event endpoint monitoring in clinical trials.Pharm Stat2019
30826660Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.Eur J Cancer2019
31104167Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer.Cancer Causes Control2019
29754777International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.Lancet2018
29975624Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).J Clin Oncol2018
30077464Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?Clin Genitourin Cancer2018
30038051Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).Cancer Epidemiol Biomarkers Prev2018
28736441Nationally representative equations that include resistance and reactance for the prediction of percent body fat in Americans.Int J Obes (Lond)2017
  • 1 - 50 of 94

Recommended Authors

Jessica A Lavery
Memorial Sloan Kettering Cancer Center
Career Start Year 2015
Number of shared co-authors 1
Martin Goros
University of Texas Health San Antonio
Career Start Year 2013
Number of shared co-authors 0
Matthew A Hathcock
Mayo Clinic
Career Start Year 2013
Number of shared co-authors 2
Jonathan G Yabes
Center for Research on Health Care, University of Pittsburgh
Career Start Year 2012
Number of shared co-authors 0
Irbaz Bin Riaz
Mayo Clinic
Career Start Year 2012
Number of shared co-authors 4
Jacob P VanHouten
Griffin Hospital
Career Start Year 2012
Number of shared co-authors 1
Phillip J Schulte
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2011
Number of shared co-authors 19
Pamala A Pawloski
HealthPartners Institute
Career Start Year 2011
Number of shared co-authors 0
Bart S Ferket
Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai
Career Start Year 2010
Number of shared co-authors 0
Inna Y Gong
University of Toronto
Career Start Year 2010
Number of shared co-authors 0
Orestis A Panagiotou
Department of Health Services, Brown University School of Public Health
Career Start Year 2010
Number of shared co-authors 1
Lihui Zhao
Feinberg School of Medicine
Career Start Year 2009
Number of shared co-authors 4
Kelley M Kidwell
University of Michigan School of Public Health ann arbor
Career Start Year 2009
Number of shared co-authors 1
Raluca Ionescu-Ittu
Analysis Group Inc.
Career Start Year 2007
Number of shared co-authors 1
Kevin F Kennedy
Saint Luke's Mid America Heart Institute
Career Start Year 2004
Number of shared co-authors 18
Rickey E Carter
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 5
Jessica K Paulus
Hospital of the University of Pennsylvania
Career Start Year 2003
Number of shared co-authors 2
Nilay D Shah
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 10
Lu Tian
Stanford University
Career Start Year 2001
Number of shared co-authors 3
Soko Setoguchi
Rutgers University Institute for Health, the State University of New Jersey
Career Start Year 2001
Number of shared co-authors 4
Lesley H Curtis
Duke Clinical Research Institute
Career Start Year 1999
Number of shared co-authors 19
Chi-Hong Tseng
David Geffen School of Medicine, University of California los angeles
Career Start Year 1998
Number of shared co-authors 0
Manisha Desai
Stanford University
Career Start Year 1997
Number of shared co-authors 4
Elizabeth Garrett-Mayer
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 2
Ewout W Steyerberg
Leiden University Medical Center
Career Start Year 1992
Number of shared co-authors 6
Madhu Mazumdar
Icahn School of Medicine at Mount Sinai
Career Start Year 1992
Number of shared co-authors 0
Todd A MacKenzie
Geisel School of Medicine at Dartmouth
Career Start Year 1992
Number of shared co-authors 3
Stuart R Lipsitz
Harvard Medical School
Career Start Year 1988
Number of shared co-authors 3
Robin Ruthazer
Tufts Clinical and Translational Science Institute, 7Tufts Medical Center
Career Start Year 1983
Number of shared co-authors 3

Collaborators

Eric D Peterson
University of Texas Southwestern Medical Center
Co-authored papers 33
Matthew T Roe
Duke Clinical Research Institute, Duke University
Co-authored papers 28
Erik Magnus Ohman
Duke University Medical Center-Duke Clinical Research Institute
Co-authored papers 14
W Brian Gibler
University of Cincinnati College of Medicine President
Co-authored papers 13
John S Rumsfeld
Stanford University
Co-authored papers 10
Al B Benson
Northwestern University Feinberg School of Medicine
Co-authored papers 8
Tracy Y Wang
Duke University
Co-authored papers 8
Edward L Giovannucci
Harvard T.H. Chan School of Public Health
Co-authored papers 8
Charles V Pollack
Thomas Jefferson University Hospital, Pennsylvania Sidney Kimmel Medical College
Co-authored papers 7
Qian Shi
117902Beijing TongRen Hospital, Capital Medical University
Co-authored papers 7
Donglin Zeng
University of North Carolina
Co-authored papers 3
John A Spertus
University of Missouri-Kansas City School of Medicine
Co-authored papers 3
Jianwen Cai
Co-authored papers 3
William F Peacock
Baylor College of Medicine
Co-authored papers 3
Steven R Alberts
Mayo Clinic
Co-authored papers 3
Christopher P Cannon
Brigham and Women's Hospital
Co-authored papers 3
June Stevens
Co-authored papers 3
Ralph G Brindis
University of California san francisco
Co-authored papers 3
James G Jollis
Duke Clinical Research Institute, Duke University School of Medicine
Co-authored papers 2
Deborah Schrag
Memorial-Sloan Kettering Cancer Center
Co-authored papers 2
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 2
Robert A Harrington
Co-authored papers 2
Richard E Shaw
California Pacific Medical Center
Co-authored papers 2
Howard L McLeod
Center for Precision Medicine and Functional Genomics, Utah Tech University
Co-authored papers 2
Sripal Bangalore
New York University Grossman School of Medicine
Co-authored papers 2
Andrew T Chan
Massachusetts General Hospital and Harvard Medical School
Co-authored papers 2
Rachel Tam
Co-authored papers 2
James W Hoekstra
Wake Forest School of Medicine
Co-authored papers 2
Elizabeth R DeLong
Duke University
Co-authored papers 2
Joseph J Larson
Division of Clinical Trials and Biostatistics, Mayo Clinic
Co-authored papers 2
Release 1.2